Axcella Health Inc

Axcella Health — Q1 2021 Earnings Presentation

31 slides from Axcella Health's earnings presentation, May 6, 2021

  1. Slide 1: Capitalizing on an Accelerated Path to Late-Stage Development

    © 2021 Axcella Health Inc. All rights reserved. NASDAQ: AXLA Capitalizing on an Accelerated Path to Late-Stage Development May 2021

  2. Slide 2: Forward-Looking Statements

    © 2021 Axcella Health Inc. All rights reserved. 2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the characteristics, competit

  3. Slide 3: About Axcella's Development Model and Clinical Approach

    © 2021 Axcella Health Inc. All rights reserved. 3 About Axcella’s Development Model and Clinical Approach EMMs have a fundamental role in biology and biological function. Using the Axcella Knowledge Base, Axcella designs and develops novel EMM compositions to engage identified biologies and pathways

  4. Slide 4: What if… more effective, safer oral multi-targeted therapies

    What if… We could now more effectively and safely treat complex, chronic diseases using oral, multi-targeted therapies composed of endogenous molecules?

  5. Slide 5: Powerful Platform and Approach; Broad Applicability

    © 2021 Axcella Health Inc. All rights reserved. 5 Powerful Platform and Approach; Broad Applicability Potential for EMM compositions to impact multiple areas with rapid clinical development paths 1. Company estimates based on Scaglione, S. et. al., J. Clin. Gastroenterol. (2015); HE Practice Guideli

  6. Slide 6: Unlocking the Potential of Endogenous Metabolic Modulators (EMMs)

    © 2021 Axcella Health Inc. All rights reserved. 6 Unlocking the Potential of Endogenous Metabolic Modulators (EMMs) EMMs act as Master Regulators and Signaling Agents in human biology Axcella’s EMM Platform: • Focused on amino acids and their derivatives; proven track record for clinical activity an

  7. Slide 7: Highly Informed, Rapid Paths to Later-Stage Clinical Trials

    © 2021 Axcella Health Inc. All rights reserved. 7 1. Paul, S. M., et. al. Nature Reviews Drug Discovery (March 2010). 2. Non-IND clinical studies enrolling diseased human subjects. Please refer to slide 3 for further detail. Timing of AXA1665 Phase 2 and AXA1125 Phase 2b clinical trials based on cur

  8. Slide 8: Potential for EMM Compositions in Many Areas

    © 2021 Axcella Health Inc. All rights reserved. 8 Potential for EMM Compositions in Many Areas • OHE • NASH Initial Focus • Mitochondrial • Atrophy • Inflammatory • Metabolism • Immunology • Neuroprotection Future Potential Initial Focus • OHE • NASH Potential Applications • Metabolism • Mitochondri

  9. Slide 9: AXA1665: Reduction in Risk of Recurrent OHE

    9© 2021 Axcella Health Inc. All rights reserved. AXA1665 Potential Indication: Reduction in Risk of Recurrent Overt Hepatic Encephalopathy (OHE) Status: Entering Phase 2

  10. Slide 10: Overt Hepatic Encephalopathy (OHE)

    © 2021 Axcella Health Inc. All rights reserved. 10 1. Company estimates based on Scaglione, S. et. al., J. Clin. Gastroenterol. (2015); HE Practice Guidelines by AASLD and EASL (2014); DelveInsight – HE Market Forecast (2019). 2. Based on currently marketed products only with potential for further e

  11. Slide 11: AXA1665: A Potential Comprehensive Treatment for OHE

    © 2021 Axcella Health Inc. All rights reserved. 11 AXA1665: A Potential Comprehensive Treatment for OHE Potential to improve – and eventually become – the standard of care Oral candidate with a multi-targeted mechanism that goes well beyond today’s ammonia-focused agents Multifactorial effects obser

  12. Slide 12: AXA1665 - A Potential Comprehensive OHE Therapy

    © 2021 Axcella Health Inc. All rights reserved. 12 Hypothesized mechanisms depicted above. Abbreviations: Asp, aspartate; Cit, citrulline; Gln, glutamine; Glu, glutamic acid; His, histidine; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; mTORC1, mammalian target of rapamycin complex 1;

  13. Slide 13: AXA1665-002: 12-Week Placebo Controlled Study

    © 2021 Axcella Health Inc. All rights reserved. 13 1. Non-IND clinical study initiated prior to therapeutic development path decision. Please refer to slide 3 for further detail. Abbreviation: BMx, biomarkers. AXA1665-002: A 12-Week Placebo Controlled Study in Subjects with Mild and Moderate Hepatic

  14. Slide 14: AXA1665-002: Improvement Noted in Key Biomarkers at Week 12

    © 2021 Axcella Health Inc. All rights reserved. 14 -30 -15 0 15 30 45 60 75 BL W2 W4 W6 W9 W12 P e rc e n ta g e C h a n g e , L S M e a n ( S E ) 1. 11, 22 and 27 subjects in placebo, AXA1665 low-dose, and AXA1665 high-dose arms, respectively, were included in the analysis; LS = Least-squares; AXA1

  15. Slide 15: Dose Dependent Improvement Across Cognitive Function Measures

    © 2021 Axcella Health Inc. All rights reserved. 15 -3 0 3 6 A b s o lu te c h a n g e , L S m e a n ( S E ), H z -0.0 -0.3 2.6 1. Considered to be a clinically relevant threshold based on PHES improvements ranging from 2.1 to 3.2 for lactulose, probiotics and LOLA in prior clinical trials. Singh, J,

  16. Slide 16: AXA1665 Phase 2 Expected to Begin in Q2 2021

    © 2021 Axcella Health Inc. All rights reserved. 16 NC: neurocognitive; fxn: function; PROs: patient reported outcomes; SOC: standard of care (lactulose ± rifaximin) AXA1665 Phase 2 Expected to Begin in Q2 2021 Efficient design to measure PHES, OHE event rates, physical function and PROs Screening 1:

  17. Slide 17: AXA1125: Non-Alcoholic Steatohepatitis (NASH)

    17© 2021 Axcella Health Inc. All rights reserved. AXA1125 Potential Indication: Non-Alcoholic Steatohepatitis (NASH) Status: Entering Phase 2b

  18. Slide 18: Nonalcoholic Steatohepatitis (NASH)

    © 2021 Axcella Health Inc. All rights reserved. 18 1. Desai, R. et al. Characterization of Polypharmacy in Patients with NAFLD. AASLD 2018 2. Global Liver Institute U.S. NASH Action Plan (Dec. 2020). 3. Younossi, Z. et al. Hepatology. Vol. 64, No. 1, 2016. Nonalcoholic Steatohepatitis (NASH) A compl

  19. Slide 19: AXA1125: A Potential First-Line Treatment for NASH

    © 2021 Axcella Health Inc. All rights reserved. 19 AXA1125: A Potential First-Line Treatment for NASH Compelling candidate for first-line monotherapy, combo and pediatric use Oral candidate with a multi-targeted mechanism aimed at metabolism, inflammation and fibrosis pathways Data to date compare f

  20. Slide 20: AXA1125 - Designed to Target Multiple Metabolic Pathways

    © 2021 Axcella Health Inc. All rights reserved. 20 Hypothesized mechanisms depicted above. AAs, amino acids; AMPK, AMP-activated protein kinase; Arg, arginine; Gln, glutamine; GSH, glutathione; Hif1α, hypoxia-inducible factor 1 alpha; GSH, glutathione; Ile, isoleucine; Leu, leucine; Nac, N-acetylcys

  21. Slide 21: Unique Impacts Across NASH Pathways in Cell Systems

    © 2021 Axcella Health Inc. All rights reserved. 21 αSMA, α-smooth muscle actin; AA, amino acid; ApoB, apolipoprotein B; CCL, C-C motif chemokine ligand; EdU, 5-ethynyl-2´-deoxyuridine; I, isoleucine; IL-4, interleukin 4; IL-6, interleukin 6; L, leucine; LIV, leucine/isoleucine/valine; LIVRQNac, 5 am

  22. Slide 22: Design of Our Most Recent Clinical Study: AXA1125-003

    © 2021 Axcella Health Inc. All rights reserved. 22 1. Non-IND clinical study initiated prior to therapeutic development path decision. Please refer to slide 3 for further detail. 2. Calorie-matched placebo control. BID, 2 times a day; BMx, biomarkers; D, Day; cT1, corrected T1; IND, investigational

  23. Slide 23: AXA1125-003 Biomarker Results

    © 2021 Axcella Health Inc. All rights reserved. 23 -0.7 -3.5-3.4 -5.3 -9 -6 -3 0 All Subjects Subjects with T2D A b s o lu te c h a n g e , m e a n ( S E ), n g / m L ProC3 -1.9 -21.4 -7.5 -16.2 -45 -30 -15 0 All Subjects Subjects with T2D R e la ti v e c h a n g e , m e a n ( S E ), % FIB-4 18.3 -4

  24. Slide 24: AXA1125: Meaningful Thresholds of Activity Achieved

    © 2021 Axcella Health Inc. All rights reserved. 24 33.0 45.5 0 10 20 30 40 50 S u b je c ts , % 33.0 63.6 0 10 20 30 40 50 60 70 S u b je c ts , % 0.0 54.5 0 20 40 60 S u b je c ts , % 1. Loomba, R. et al. Hepatology (January 2020). 2. Loomba, R. et al. Gastroenterology (January 2019). 3. Dennis, A.

  25. Slide 25: AXA1125 IND Recently Cleared; Phase 2b Expected Q2 2021

    © 2021 Axcella Health Inc. All rights reserved. 25 D1: Biopsy Fibroscan MRI-PDFF W48: Biopsy Fibroscan MRI-PDFF W24: Fibroscan MRI-PDFF W12: Fibroscan MRI-PDFF AXA1125 Ph2b initiation based on current expectations and subject to risks AXA1125 IND Recently Cleared Initiation of Phase 2b trial expecte

  26. Slide 26: Summary

    © 2021 Axcella Health Inc. All rights reserved. 26 Summary

  27. Slide 27: Strategy Intended to Protect Axcella's First-Mover Advantages

    © 2021 Axcella Health Inc. All rights reserved. 27 0 0 3 6 12/31/17 12/31/18 12/31/19 12/31/20 11 14 18 22 12/31/17 12/31/18 12/31/19 12/31/20 33 48 127 283 12/31/17 12/31/18 12/31/19 12/31/20 Strategy Intended to Protect Axcella’s First-Mover Advantages WORLDWIDE PATENT FAMILIES WORLDWIDE PATENTS P

  28. Slide 28: Well Capitalized for Next Steps

    © 2021 Axcella Health Inc. All rights reserved. 28 Well Capitalized for Next Steps $93 million in cash and marketable securities at March 31, providing runway into Q3 of 2022 (in thousands) March 31, 2021 Assets: Cash and cash equivalents $43,049 Marketable securities 49,909 Other assets 1,522 Total

  29. Slide 29: Axcella's Experienced Leadership

    © 2021 Axcella Health Inc. All rights reserved. 29 Axcella’s Experienced Leadership Bill Hinshaw President and CEO Alison Schecter, MD President, R&D Laurent Chardonnet SVP and CFO Paul Fehlner, PhD, JD SVP and Chief Legal Officer BOARD OF DIRECTORS David Epstein (Chairman) Executive Partner Flagshi

  30. Slide 30: Thank You

    840 Memorial Drive, Third Floor Cambridge, MA 02139 www.axcellahealth.com Thank You NASDAQ: AXLA © 2021 Axcella Health Inc. All rights reserved.

  31. Slide 31: Reference Materials

    © 2021 Axcella Health Inc. All rights reserved. 31 Reference Materials Axcella’s EMM Platform and Therapeutic Approach Use of Amino Acids as Therapeutics (iScience) Combinatorial approach to EMMs (ICFSR) AXA1665 for OHE AXA1665-001 Data (Clinical and Translational Gastroenterology) AXA1125 for NASH

Axcella Health — Q1 2021 Earnings Presentation on 6ix